Skip to main content

Table 2 Continuous outcome measures

From: Combined use of topical intraarticular tranexamic acid and rivaroxaban in total knee arthroplasty safely reduces blood loss, transfusion rates, and wound complications without increasing the risk of thrombosis

 

Rivaroxaban only

(n = 52)

Rivaroxaban + IA TXA

(n = 52)

p-value

Total drain output (mL)

1021.4 (893.9–1148.9)

419.1 (349.9–488.3)

< 0.001

Nadir Hb during hospital stay (mL)

8.2 (7.9–8.6)

9.0 (8.8–9.3)

< 0.001

Maximum decrease in Hb (g/dL)

4.2 (3.9–4.6)

3.6 (3.1–4.0)

0.015

Total blood loss (mL)

1260.1 (1168.7–1351.6)

1008.2 (910.3–1106.2)

< 0.001

  1. All values presented as means (95% confidence interval) and compared using independent t-tests